Breakthrough sleep apnea medication AD109 shows promising results in phase 3 trials, potentially helping 30 million Americans with the condition.
Nearly five years after the Philips Respironics recall reshaped the CPAP market, respondents to a recent HME Newspoll say ...
BLACKSHEARS, GA, UNITED STATES, January 6, 2026 /EINPresswire.com/ — REMSleep Holdings, Inc. (OTCQB: RMSL), developer of the FDA-cleared DeltaWave™ CPAP mask ...
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a ...
Company Transitions from Infrastructure Buildout to Active Market Execution as Expanded 510(k) Review Enters Final Stages REMSleep Holdings, Inc. (OTCQB:RMSL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results